Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Study Links Sex Hormones to Childhood Cancer

December 1, 1996
Publication
Article
OncologyONCOLOGY Vol 10 No 12
Volume 10
Issue 12

Women who take sex hormones before and during pregnancy are three times more likely to have children who develop cancer, according to researchers at Roswell Park Cancer Institute.

Women who take sex hormones before and during pregnancy are threetimes more likely to have children who develop cancer, accordingto researchers at Roswell Park Cancer Institute.

Epidemiologist Arthur Michalek, phd, associate director of theDepartment of Education, and colleagues report that neuroblastoma,the most common type of childhood cancer, is linked to a mother'suse of sex hormones to increase fertility, control vaginal bleeding,or prevent miscarriages.

Neuroblastoma tumors are generally found in adrenal glands. Althoughcancer among young children is rare, neuroblastoma accounts forone-quarter of all childhood cancers and is diagnosed in about500 children annually.

Previously, the low incidence rate of neuroblastomas preventedthe detailed investigation of risk factors associated with thisdisease.

In the Roswell Park study, the first and largest of its kind,Dr. Michalek and associates compared the results of interviewswith 183 women whose children were diagnosed with neuroblastomaand 372 women with healthy offspring. Those mothers who used sexhormones were more likely to have children who were later diagnosedwith the disease.

Male children appeared to be at higher risk for the disease thanfemales, with an average age at diagnosis of 18 months.

Women who took sex hormones to increase fertility proved to beat greatest risk. "The sizable numbers of case and controlmothers interviewed [increased] the statistical power of thisstudy and enabled the detection of subtle risk differences,"explained Michalek.

Although not addressed in the study, the researchers suggest thatother potential risk factors, such as the routine use of oralcontraceptives, be examined in mothers of children diagnosed withneuroblastoma.

A Surprising Development

In a surprising development, vitamins used during pregnancy seemedto offer the unborn child some protection against cancer. Thedata, however, were based on a mother's self-reported use of vitamins,and this aspect of the investigation requires more controlledstudy, Michalek noted.

Articles in this issue

One in Three Newly Diagnosed Cancer Patients Now Receives Radiation Therapy
Study Links Sex Hormones to Childhood Cancer
Scientists Confirm Natural Resistance to HIV-1
US Prostate Cancer Rates Dropping for White Men; Stabilizing for African-American Men
NCI's Largest Cancer Screening Trial Now Enrolling Men and Women Ages 55 to 74
Radiation After Lumpectomy for Node-Negative Breast Cancer Reduces Disease Recurrence But Not Overall Mortality

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Related Content

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent with IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Optimizing Care Planning for Variant Histology Populations at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Bradley G. Somer, MD
September 11th 2025
Podcast

In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Tim Cortese
September 11th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 11th 2025
Podcast

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Ariana Pelosci
September 11th 2025
Article

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 11th 2025
Article
Related Content

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent with IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Optimizing Care Planning for Variant Histology Populations at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Bradley G. Somer, MD
September 11th 2025
Podcast

In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Tim Cortese
September 11th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 11th 2025
Podcast

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Ariana Pelosci
September 11th 2025
Article

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 11th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.